Stem cell virus therapy for recurrent brain tumors
Part of Cancer clinical trials.
This trial tests a new treatment that uses specially modified stem cells (taken from donors) to deliver a virus directly into the tumor during surgery. The goal is to see if it is safe and effective for brain tumors that have come back after standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of brain tumor called a high-grade glioma that has come back after standard treatment (radiation and temozolomide).
- You must be able to have surgery to remove the tumor.
- Your tumor must be a single spot, not spread to multiple areas of the brain.
- You need to have enough healthy blood cells and liver/kidney function (these will be checked with blood tests).
- You must be willing to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
This trial tests a virus-based treatment for glioblastoma that has come back after standard therapies. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone.
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
This trial tests a new kind of cell therapy called CAR-T, made from donor cells, to treat glioblastoma that has come back. The treatment targets a specific marker on the tumor (B7H3) and is injected into the brain to attack the cancer cells.
Hear when a new Currently Only Enrolling Glioblastoma Patients at First Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.